Page last updated: 2024-11-12

adh-1 pepide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

ADH-1 pepide: a cyclic pentapeptide and N-cadherin antagonist targeting cancer vascularization [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9916058
CHEMBL ID3818130
SCHEMBL ID13857500
MeSH IDM0508412

Synonyms (26)

Synonym
adh-10001
exherin
nsc-729477
229971-81-7
adh-1
C518575000
adh-1 pepide
adh 1
b058me29vu ,
nsc 729477
unii-b058me29vu
l-cysteinamide, n-acetyl-l-cysteinyl-l-histidyl-l-alanyl-l-valyl-, cyclic (1-5)-disulfide
cys-his-ala-val-cys
CS-3450
DTXSID4044036
SCHEMBL13857500
HY-13541
CHEMBL3818130
AKOS030526741
Q4651113
(4r,7s,10s,13s,16r)-13-((1h-imidazol-5-yl)methyl)-16-acetamido-7-isopropyl-10-methyl-6,9,12,15-tetraoxo-1,2-dithia-5,8,11,14-tetraazacycloheptadecane-4-carboxamide
D83667
229971-81-7 (free base)
exherin free base
EX-A3549
(4r,7s,10s,13s,16r)-16-acetamido-13-(1h-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" A phase 1 dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with in-transit extremity melanoma was performed."( A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma.
Augustine, CK; Beasley, GM; McMahon, N; Norris, R; Peters, WP; Peterson, B; Ross, MI; Sanders, G; Selim, MA; Tyler, DS, 2009
)
0.35
"Systemic ADH-1 at a dose of 4000 mg on Days 1 and 8 in combination with melphalan via isolated limb infusion is a well-tolerated, novel targeted therapy approach to regionally advanced melanoma."( A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma.
Augustine, CK; Beasley, GM; McMahon, N; Norris, R; Peters, WP; Peterson, B; Ross, MI; Sanders, G; Selim, MA; Tyler, DS, 2009
)
0.35
" In a preclinical animal model, systemic ADH-1 given with regional melphalan demonstrated synergistic antitumor activity, and in a phase I trial with M-ILI it had minimal toxicity."( Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma.
Augustine, CK; Beasley, GM; Grobmyer, SR; Hochwald, SN; Peterson, B; Riboh, JC; Ross, MI; Royal, R; Tyler, DS; Zager, JS, 2011
)
0.37

Dosage Studied

ExcerptRelevanceReference
"Isolated limb infusion (ILI) with melphalan (M-ILI) dosing corrected for ideal body weight (IBW) is a well-tolerated treatment for patients with in-transit melanoma with a 29% complete response rate."( Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma.
Augustine, CK; Beasley, GM; Grobmyer, SR; Hochwald, SN; Peterson, B; Riboh, JC; Ross, MI; Royal, R; Tyler, DS; Zager, JS, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1308393Inhibition of N-cadherin-Fc chimeric protein binding to N-cadherin in human SKOV3 cells at 1 mM preincubated for 1 hr followed by N-cadherin-Fc addition measured after 2 hrs by ELISA relative to control2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Crystal Structure of Human E-Cadherin-EC1EC2 in Complex with a Peptidomimetic Competitive Inhibitor of Cadherin Homophilic Interaction.
AID1308390Inhibition of E-cadherin-Fc chimeric protein binding to E-cadherin in human OAW42 cells at 2 mM preincubated for 1 hr followed by E-cadherin-Fc addition measured after 2 hrs by ELISA relative to control2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Crystal Structure of Human E-Cadherin-EC1EC2 in Complex with a Peptidomimetic Competitive Inhibitor of Cadherin Homophilic Interaction.
AID1308391Inhibition of recombinant N-cadherin-Fc chimeric protein (unknown origin) homodimerization at 10 uM preincubated for 30 mins followed by N-cadherin-Fc addition by surface plasmon resonance analysis relative to control2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Crystal Structure of Human E-Cadherin-EC1EC2 in Complex with a Peptidomimetic Competitive Inhibitor of Cadherin Homophilic Interaction.
AID1308392Inhibition of N-cadherin-Fc chimeric protein binding to N-cadherin in human SKOV3 cells at 2 mM preincubated for 1 hr followed by N-cadherin-Fc addition measured after 2 hrs by ELISA relative to control2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Crystal Structure of Human E-Cadherin-EC1EC2 in Complex with a Peptidomimetic Competitive Inhibitor of Cadherin Homophilic Interaction.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (28.57)29.6817
2010's7 (50.00)24.3611
2020's3 (21.43)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (14.29%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (7.14%)4.05%
Observational0 (0.00%)0.25%
Other11 (78.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]